Skip to main content
. 2024 Aug 11;15:6870. doi: 10.1038/s41467-024-51315-8

Fig. 1. Survival of patients with stable or progressive disease.

Fig. 1

OS (A) and on-treatment survival (B) of patients with either stable (primary; black) or progressive (recurrent; red) disease at the time of personalized peptide vaccine administration (P < 0.0001). Statistical significance of survival differences was computed using the log-rank test. Source data are provided as a Source Data file.